Table 4 Impact of resveratrol on the expression of genes in the context of gastrointestinal disorders
Type of disease | Dose range | Cell line | Target | Pathway | Function | Refs. |
|---|---|---|---|---|---|---|
In vivo studies | ||||||
Intestinal Injury | 20 mg/kg | – | TNF-α, NF-κB, IL-1β | PI3K/AKT/mTOR | RVT via modulating PI3K/AKT/mTOR pathway could reduce intestinal inflammation in irradiated rats | [43] |
Liver Fibrosis (LF) | 40–200 mg/kg, 10–50 mg/mL | HSC-T6 | miR-20a, α-SMA, TIMP-1, TGF-β1, LC3-II, LC3-I, Beclin1, Atg7 | PTEN/PI3K/AKT | RVT via the miR-20a-mediated activation of the PTEN/PI3K/AKT pathway can inhibit LF | [46] |
LF | 20–50 mg/kg, 0–125 μg/mL | LX-2 | α-SMA, Collagen-I, IκB-α, P65 | AKT, NF-κB | RVT via the AKT/NF-κB pathways could attenuate the progression of LF | [47] |
In vitro studies | ||||||
Intestinal Damage | 0–50 μM | IPEC-J2, 293 T | Claudin-1, Occludin, ZO-1, Keap1, NFE2L2, SOD-1, HO-1, CAT, GSX-1, Nrf2 | PI3K/AKT | RVT via the PI3K/AKT-mediated Nrf2 pathway could protect IPEC-J2 cells against oxidative stress | [44] |
Hepatic Fibrosis | 3.125, 6.25, 12.5 μM | T-HSC/Cl-6 | Collagen-I, α-SMA, TLR4, M8, LXR-α, LXR-β | PI3K/AKT, NF-κB | RVT via modulating NF-κB and the PI3K/AKT pathway could regulate activated hepatic stellate cells (HSCs) | [45] |